Explore how HIS mice enable the in vivo evaluation of checkpoint inhibitors, bispecific antibodies, and cancer vaccines. These models replicate human immune-tumor interactions and help predict treatment outcomes more accurately than traditional mice.

Cyagen provides one-stop neuroscience CRO solutions from custom animal model generation to behavioral and molecular efficacy evaluation, enabling precise, rapid, and reliable preclinical research.

Achieve reliable pancreas-specific gene recombination with the Pdx1-CreERT2 model. This tamoxifen-inducible line improves over traditional Cre models by reducing background activity and increasing recombination efficiency in islet cells.

Learn how the B6-hIGHMBP2 humanized mouse model supports rare disease research for IGHMBP2-related conditions like SMARD1 and CMT2S. This model expresses the full human gene and enables evaluation of gene and nucleic acid therapies.

See how induced pluripotent stem cells enable precision models for neurodegeneration, cardiac repair, immune cell therapy, and high-throughput drug discovery. These platforms provide scalable, human-relevant solutions for complex diseases.

Discover how Adipoq-iCre mice enable precise gene targeting in white and brown adipose tissues. Learn how this model, when crossed with tdTomato reporters, supports clear fluorescent detection and enhances research on fat metabolism.

Explore how intestinal epithelial cells regulate CD4+CD8αα+ IEL differentiation via MHC II and PD-L1 expression in response to IFN-γ and microbiota. Learn how Cyagen’s mouse models, including IEC-specific knockouts and GF mice, support immunological studies into gut barrier integrity and immune cell education.

Discover how NKG-hIL15 and huHSC-NKG-hIL15 mice enable high-fidelity reconstitution of functional human NK cells. With stable expression of human IL-15, these models support in-depth evaluation of NK-targeted drugs, offering translational relevance and expanded immune functionality for preclinical research.

Flow cytometry plays a critical role in preclinical CAR-T workflows, from target antigen validation and virus titer assessment to CAR expression, phenotyping, and in vivo tracking. Discover how Cyagen integrates this powerful technology across cell therapy pipelines to support rapid and reliable development.

Cyagen is seeking a dynamic and strategic Business Development Manager to lead market expansion efforts in South Korea. This role focuses on driving sales growth, building lasting customer relationships, and executing market-specific strategies to enhance Cyagen’s presence and revenue in the Korean life sciences sector.